Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC.ASMB · Entity 5216 | See Remarks | March 29, 2019 | April 02, 2019 |
| Applied Molecular Transport Inc.AMTI · Entity 95737 | Director | January 27, 2022 | January 31, 2022 |
| Beam Therapeutics Inc.BEAM · Entity 4227 | Director | June 03, 2026 | June 05, 2026 |
| Unity Biotechnology, Inc.UBX · Entity 77428 | Director | June 24, 2021 | June 28, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ASSEMBLY BIOSCIENCES, INC.
Report date March 29, 2019 · Filed April 02, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 117,500 |
Reported balance
After 2019-03-29 transaction · row 1
1 source rowRow 1 · 2019-03-29 · Grant · Acquired 17,500 · Balance 117,500 F1: Grant of restricted stock units. The restricted stock units vest in four equal installments, assuming continuous service on each vesting date, as follows: March 29, 2020; March 29, 2021; March 29, 2022; and March 29, 2023. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.69 · Expires 2029-03-29 | Direct | 35,000 |
Reported balance
After 2019-03-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-03-29 · Grant · Acquired 35,000 · Balance 35,000 F2: Grant of stock options. The stock options vest over four years, assuming continuous service on each vesting date, as follows: 25% shall vest on the first anniversary of the date of grant, March 29, 2020; and the remaining 75% shall vest in 36 approximately equal monthly installments, with the options becoming fully vested on March 29, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units. The restricted stock units vest in four equal installments, assuming continuous service on each vesting date, as follows: March 29, 2020; March 29, 2021; March 29, 2022; and March 29, 2023.
F2: Grant of stock options. The stock options vest over four years, assuming continuous service on each vesting date, as follows: 25% shall vest on the first anniversary of the date of grant, March 29, 2020; and the remaining 75% shall vest in 36 approximately equal monthly installments, with the options becoming fully vested on March 29, 2023.
Applied Molecular Transport Inc.
Report date January 27, 2022 · Filed January 31, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.01 · Expires 2032-01-27 | Direct | 300,000 |
Reported balance
After 2022-01-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-01-27 · Grant · Acquired 300,000 · Balance 300,000 F1: 1/48th of the shares subject to the option shall vest and become exercisable on the Exercisable Date set forth above and 1/48th of the shares subject to the option shall vest monthly thereafter, provided that Reporting Person remains a service provider to the Issuer on each such vest date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares subject to the option shall vest and become exercisable on the Exercisable Date set forth above and 1/48th of the shares subject to the option shall vest monthly thereafter, provided that Reporting Person remains a service provider to the Issuer on each such vest date.
Beam Therapeutics Inc.
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.55 · Expires 2036-06-03 | Direct | 19,676 |
Reported balance
After 2026-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 19,676 · Balance 19,676 F1: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.
Unity Biotechnology, Inc.
Report date June 24, 2021 · Filed June 28, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.18 · Expires 2031-06-23 | Direct | 25,000 |
Reported balance
After 2021-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-24 · Grant · Acquired 25,000 · Balance 25,000 F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the one-year anniversary measured from June 24, 2021 or (ii) the date of the 2022 Annual Meeting of the Issuer's stockholders, assuming continuous service as a Director until such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the one-year anniversary measured from June 24, 2021 or (ii) the date of the 2022 Annual Meeting of the Issuer's stockholders, assuming continuous service as a Director until such vesting date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Kezar Life Sciences, Inc.
Report date May 11, 2026 · Filed May 11, 2026
Section 16 reporting ended · disclosed 2026-05-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.70 · Expires 2027-10-09 | Direct | 0 |
Reported balance
After 2026-05-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-11 · Disposition to issuer · Disposed 3,742 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 30, 2026 (the "Merger Agreement"), each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than $6.955 per share ("Cash Amount") (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist after completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of May 11, 2026, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time") , and no consideration was delivered in exchange for such Out-of-the-Money Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.10 · Expires 2028-04-15 | Direct | 0 |
Reported balance
After 2026-05-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-11 · Disposition to issuer · Disposed 889 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 30, 2026 (the "Merger Agreement"), each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than $6.955 per share ("Cash Amount") (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist after completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of May 11, 2026, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time") , and no consideration was delivered in exchange for such Out-of-the-Money Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.40 · Expires 2033-06-14 | Direct | 0 |
Reported balance
After 2026-05-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-11 · Disposition to issuer · Disposed 3,500 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 30, 2026 (the "Merger Agreement"), each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than $6.955 per share ("Cash Amount") (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist after completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of May 11, 2026, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time") , and no consideration was delivered in exchange for such Out-of-the-Money Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.70 · Expires 2034-06-19 | Direct | 0 |
Reported balance
After 2026-05-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-11 · Disposition to issuer · Disposed 5,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each Company Stock Option that had a per share exercise price less than the Cash Amount (an "In-the-Money Option") was automatically cancelled and converted at the Effective Time into the right to receive (A) an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share underlying such Company Stock Option at the Effective Time by (y) the number of shares underlying such In-the-Money Option, subject to the terms and conditions specified in the Merger Agreement and (B) one CVR in respect of each share underlying such In-the-Money Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.46 · Expires 2035-06-17 | Direct | 0 |
Reported balance
After 2026-05-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-11 · Disposition to issuer · Disposed 5,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each Company Stock Option that had a per share exercise price less than the Cash Amount (an "In-the-Money Option") was automatically cancelled and converted at the Effective Time into the right to receive (A) an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share underlying such Company Stock Option at the Effective Time by (y) the number of shares underlying such In-the-Money Option, subject to the terms and conditions specified in the Merger Agreement and (B) one CVR in respect of each share underlying such In-the-Money Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.80 · Expires 2029-06-24 | Direct | 0 |
Reported balance
After 2026-05-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-05-11 · Disposition to issuer · Disposed 889 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 30, 2026 (the "Merger Agreement"), each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than $6.955 per share ("Cash Amount") (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist after completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of May 11, 2026, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time") , and no consideration was delivered in exchange for such Out-of-the-Money Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.80 · Expires 2030-06-23 | Direct | 0 |
Reported balance
After 2026-05-11 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-05-11 · Disposition to issuer · Disposed 889 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 30, 2026 (the "Merger Agreement"), each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than $6.955 per share ("Cash Amount") (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist after completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of May 11, 2026, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time") , and no consideration was delivered in exchange for such Out-of-the-Money Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.80 · Expires 2031-06-27 | Direct | 0 |
Reported balance
After 2026-05-11 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-05-11 · Disposition to issuer · Disposed 2,600 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 30, 2026 (the "Merger Agreement"), each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than $6.955 per share ("Cash Amount") (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist after completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of May 11, 2026, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time") , and no consideration was delivered in exchange for such Out-of-the-Money Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.80 · Expires 2032-05-11 | Direct | 0 |
Reported balance
After 2026-05-11 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-05-11 · Disposition to issuer · Disposed 2,600 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 30, 2026 (the "Merger Agreement"), each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than $6.955 per share ("Cash Amount") (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist after completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of May 11, 2026, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time") , and no consideration was delivered in exchange for such Out-of-the-Money Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.80 · Expires 2032-06-15 | Direct | 0 |
Reported balance
After 2026-05-11 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-05-11 · Disposition to issuer · Disposed 2,600 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 30, 2026 (the "Merger Agreement"), each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than $6.955 per share ("Cash Amount") (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist after completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of May 11, 2026, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time") , and no consideration was delivered in exchange for such Out-of-the-Money Option. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 30, 2026 (the "Merger Agreement"), each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than $6.955 per share ("Cash Amount") (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist after completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of May 11, 2026, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time") , and no consideration was delivered in exchange for such Out-of-the-Money Option.
F2: Pursuant to the terms of the Merger Agreement, each Company Stock Option that had a per share exercise price less than the Cash Amount (an "In-the-Money Option") was automatically cancelled and converted at the Effective Time into the right to receive (A) an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share underlying such Company Stock Option at the Effective Time by (y) the number of shares underlying such In-the-Money Option, subject to the terms and conditions specified in the Merger Agreement and (B) one CVR in respect of each share underlying such In-the-Money Option.
Nuvation Bio Inc.
Report date February 10, 2021 · Filed February 26, 2021
Section 16 reporting ended · disclosed 2021-02-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 25,000 |
Reported balance
After 2021-02-10 transaction · row 1
1 source rowRow 1 · 2021-02-10 · Exercise / conversion · Acquired 25,000 · Balance 25,000 F1: Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc., was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date. |
| Class B Common StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-02-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-02-10 · Exercise / conversion · Disposed 25,000 · Balance 0 F1: Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc., was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc., was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2026 Filed Jun 5, 2026 20:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 19,676 | $0.00 Strike: $29.55 | $0.00 |
DisclosureSEC source: 0001193125-26-259519 · ownership.xml · derivative · entry 1 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,676 Underlying: Common Stock · 19,676 shares Expires 2036-06-03 F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date. Read SEC document |
| May 11, 2026 Filed May 11, 2026 20:30 UTC | Kezar Life Sciences, Inc. KZR · Entity 12111 | Disposition to issuerStock Option (right to buy) · Derivative | 2,600 | $0.00 Strike: $22.80 | $0.00 |
DisclosureSEC source: 0001396943-26-000002 · form4-05112026_040507.xml · derivative · entry 10 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,600 shares Expires 2032-06-15 F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 30, 2026 (the "Merger Agreement"), each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than $6.955 per share ("Cash Amount") (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist after completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of May 11, 2026, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time") , and no consideration was delivered in exchange for such Out-of-the-Money Option. Read SEC document |
| May 11, 2026 Filed May 11, 2026 20:30 UTC | Kezar Life Sciences, Inc. KZR · Entity 12111 | Disposition to issuerStock Option (right to buy) · Derivative | 2,600 | $0.00 Strike: $22.80 | $0.00 |
DisclosureSEC source: 0001396943-26-000002 · form4-05112026_040507.xml · derivative · entry 9 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,600 shares Expires 2032-05-11 F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 30, 2026 (the "Merger Agreement"), each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than $6.955 per share ("Cash Amount") (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist after completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of May 11, 2026, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time") , and no consideration was delivered in exchange for such Out-of-the-Money Option. Read SEC document |
| May 11, 2026 Filed May 11, 2026 20:30 UTC | Kezar Life Sciences, Inc. KZR · Entity 12111 | Disposition to issuerStock Option (right to buy) · Derivative | 2,600 | $0.00 Strike: $22.80 | $0.00 |
DisclosureSEC source: 0001396943-26-000002 · form4-05112026_040507.xml · derivative · entry 8 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,600 shares Expires 2031-06-27 F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 30, 2026 (the "Merger Agreement"), each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than $6.955 per share ("Cash Amount") (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist after completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of May 11, 2026, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time") , and no consideration was delivered in exchange for such Out-of-the-Money Option. Read SEC document |
| May 11, 2026 Filed May 11, 2026 20:30 UTC | Kezar Life Sciences, Inc. KZR · Entity 12111 | Disposition to issuerStock Option (right to buy) · Derivative | 889 | $0.00 Strike: $22.80 | $0.00 |
DisclosureSEC source: 0001396943-26-000002 · form4-05112026_040507.xml · derivative · entry 7 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 889 shares Expires 2030-06-23 F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 30, 2026 (the "Merger Agreement"), each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than $6.955 per share ("Cash Amount") (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist after completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of May 11, 2026, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time") , and no consideration was delivered in exchange for such Out-of-the-Money Option. Read SEC document |
| May 11, 2026 Filed May 11, 2026 20:30 UTC | Kezar Life Sciences, Inc. KZR · Entity 12111 | Disposition to issuerStock Option (right to buy) · Derivative | 889 | $0.00 Strike: $22.80 | $0.00 |
DisclosureSEC source: 0001396943-26-000002 · form4-05112026_040507.xml · derivative · entry 6 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 889 shares Expires 2029-06-24 F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 30, 2026 (the "Merger Agreement"), each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than $6.955 per share ("Cash Amount") (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist after completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of May 11, 2026, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time") , and no consideration was delivered in exchange for such Out-of-the-Money Option. Read SEC document |
| May 11, 2026 Filed May 11, 2026 20:30 UTC | Kezar Life Sciences, Inc. KZR · Entity 12111 | Disposition to issuerStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $4.46 | $0.00 |
DisclosureSEC source: 0001396943-26-000002 · form4-05112026_040507.xml · derivative · entry 5 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2035-06-17 F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each Company Stock Option that had a per share exercise price less than the Cash Amount (an "In-the-Money Option") was automatically cancelled and converted at the Effective Time into the right to receive (A) an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share underlying such Company Stock Option at the Effective Time by (y) the number of shares underlying such In-the-Money Option, subject to the terms and conditions specified in the Merger Agreement and (B) one CVR in respect of each share underlying such In-the-Money Option. Read SEC document |
| May 11, 2026 Filed May 11, 2026 20:30 UTC | Kezar Life Sciences, Inc. KZR · Entity 12111 | Disposition to issuerStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $6.70 | $0.00 |
DisclosureSEC source: 0001396943-26-000002 · form4-05112026_040507.xml · derivative · entry 4 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2034-06-19 F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each Company Stock Option that had a per share exercise price less than the Cash Amount (an "In-the-Money Option") was automatically cancelled and converted at the Effective Time into the right to receive (A) an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share underlying such Company Stock Option at the Effective Time by (y) the number of shares underlying such In-the-Money Option, subject to the terms and conditions specified in the Merger Agreement and (B) one CVR in respect of each share underlying such In-the-Money Option. Read SEC document |
| May 11, 2026 Filed May 11, 2026 20:30 UTC | Kezar Life Sciences, Inc. KZR · Entity 12111 | Disposition to issuerStock Option (right to buy) · Derivative | 3,500 | $0.00 Strike: $26.40 | $0.00 |
DisclosureSEC source: 0001396943-26-000002 · form4-05112026_040507.xml · derivative · entry 3 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,500 shares Expires 2033-06-14 F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 30, 2026 (the "Merger Agreement"), each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than $6.955 per share ("Cash Amount") (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist after completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of May 11, 2026, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time") , and no consideration was delivered in exchange for such Out-of-the-Money Option. Read SEC document |
| May 11, 2026 Filed May 11, 2026 20:30 UTC | Kezar Life Sciences, Inc. KZR · Entity 12111 | Disposition to issuerStock Option (right to buy) · Derivative | 889 | $0.00 Strike: $59.10 | $0.00 |
DisclosureSEC source: 0001396943-26-000002 · form4-05112026_040507.xml · derivative · entry 2 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 889 shares Expires 2028-04-15 F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 30, 2026 (the "Merger Agreement"), each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than $6.955 per share ("Cash Amount") (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist after completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of May 11, 2026, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time") , and no consideration was delivered in exchange for such Out-of-the-Money Option. Read SEC document |
| May 11, 2026 Filed May 11, 2026 20:30 UTC | Kezar Life Sciences, Inc. KZR · Entity 12111 | Disposition to issuerStock Option (right to buy) · Derivative | 3,742 | $0.00 Strike: $23.70 | $0.00 |
DisclosureSEC source: 0001396943-26-000002 · form4-05112026_040507.xml · derivative · entry 1 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,742 shares Expires 2027-10-09 F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 30, 2026 (the "Merger Agreement"), each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than $6.955 per share ("Cash Amount") (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist after completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of May 11, 2026, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time") , and no consideration was delivered in exchange for such Out-of-the-Money Option. Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 21:00 UTC | Kezar Life Sciences, Inc. KZR · Entity 12111 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $4.46 | $0.00 |
DisclosureSEC source: 0001415889-25-017967 · form4-06232025_050606.xml · derivative · entry 1 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2035-06-17 F1 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option shall vest on 6/18/2026, subject to Reporting Person continuing to provide service through such date. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 20:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 33,662 | $0.00 Strike: $17.15 | $0.00 |
DisclosureSEC source: 0000950170-25-083050 · ownership.xml · derivative · entry 1 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,662 Underlying: Common Stock · 33,662 shares Expires 2035-06-04 F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 20:20 UTC | Kezar Life Sciences, Inc. KZR · Entity 12111 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0001415889-24-017837 · form4-06212024_040605.xml · derivative · entry 1 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-06-19 F1 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option shall vest on 6/20/2025, subject to Reporting Person continuing to provide service through such date. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:45 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 23,114 | $0.00 Strike: $24.49 | $0.00 |
DisclosureSEC source: 0000950170-24-070783 · ownership.xml · derivative · entry 1 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,114 Underlying: Common Stock · 23,114 shares Expires 2034-06-05 F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date. Read SEC document |
| July 24, 2023 Filed Jul 26, 2023 20:57 UTC | Kezar Life Sciences, Inc. KZR · Entity 12111 | GrantStock Option (Right to Buy) · Derivative | 26,000 | Not disclosed Strike: $2.28 | Not disclosed |
DisclosureSEC source: 0001209191-23-043425 · doc4.xml · derivative · entry 10 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2032-06-15 F2 · price: On July 24, 2023, the option originally granted to the Reporting Person was amended to reduce the exercise price to $2.28 per share. All of the other terms of the option remain unchanged. F1 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| July 24, 2023 Filed Jul 26, 2023 20:57 UTC | Kezar Life Sciences, Inc. KZR · Entity 12111 | Disposition to issuerStock Option (Right to Buy) · Derivative | 26,000 | Not disclosed Strike: $4.80 | Not disclosed |
DisclosureSEC source: 0001209191-23-043425 · doc4.xml · derivative · entry 9 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,000 shares Expires 2032-06-15 F2 · price: On July 24, 2023, the option originally granted to the Reporting Person was amended to reduce the exercise price to $2.28 per share. All of the other terms of the option remain unchanged. F1 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| July 24, 2023 Filed Jul 26, 2023 20:57 UTC | Kezar Life Sciences, Inc. KZR · Entity 12111 | GrantStock Option (Right to Buy) · Derivative | 26,000 | Not disclosed Strike: $2.28 | Not disclosed |
DisclosureSEC source: 0001209191-23-043425 · doc4.xml · derivative · entry 8 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2032-05-11 F2 · price: On July 24, 2023, the option originally granted to the Reporting Person was amended to reduce the exercise price to $2.28 per share. All of the other terms of the option remain unchanged. F3 · derivative.exercise_date: One thirty-sixth (1/36th) of the shares vested or shall vest on a monthly basis commencing on May 12, 2022, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| July 24, 2023 Filed Jul 26, 2023 20:57 UTC | Kezar Life Sciences, Inc. KZR · Entity 12111 | Disposition to issuerStock Option (Right to Buy) · Derivative | 26,000 | Not disclosed Strike: $5.52 | Not disclosed |
DisclosureSEC source: 0001209191-23-043425 · doc4.xml · derivative · entry 7 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,000 shares Expires 2032-05-11 F2 · price: On July 24, 2023, the option originally granted to the Reporting Person was amended to reduce the exercise price to $2.28 per share. All of the other terms of the option remain unchanged. F3 · derivative.exercise_date: One thirty-sixth (1/36th) of the shares vested or shall vest on a monthly basis commencing on May 12, 2022, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| July 24, 2023 Filed Jul 26, 2023 20:57 UTC | Kezar Life Sciences, Inc. KZR · Entity 12111 | GrantStock Option (Right to Buy) · Derivative | 26,000 | Not disclosed Strike: $2.28 | Not disclosed |
DisclosureSEC source: 0001209191-23-043425 · doc4.xml · derivative · entry 6 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2031-06-27 F2 · price: On July 24, 2023, the option originally granted to the Reporting Person was amended to reduce the exercise price to $2.28 per share. All of the other terms of the option remain unchanged. F1 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| July 24, 2023 Filed Jul 26, 2023 20:57 UTC | Kezar Life Sciences, Inc. KZR · Entity 12111 | Disposition to issuerStock Option (Right to Buy) · Derivative | 26,000 | Not disclosed Strike: $5.59 | Not disclosed |
DisclosureSEC source: 0001209191-23-043425 · doc4.xml · derivative · entry 5 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,000 shares Expires 2031-06-27 F2 · price: On July 24, 2023, the option originally granted to the Reporting Person was amended to reduce the exercise price to $2.28 per share. All of the other terms of the option remain unchanged. F1 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| July 24, 2023 Filed Jul 26, 2023 20:57 UTC | Kezar Life Sciences, Inc. KZR · Entity 12111 | GrantStock Option (Right to Buy) · Derivative | 8,896 | Not disclosed Strike: $2.28 | Not disclosed |
DisclosureSEC source: 0001209191-23-043425 · doc4.xml · derivative · entry 4 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,896 Underlying: Common Stock · 8,896 shares Expires 2030-06-23 F2 · price: On July 24, 2023, the option originally granted to the Reporting Person was amended to reduce the exercise price to $2.28 per share. All of the other terms of the option remain unchanged. F1 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| July 24, 2023 Filed Jul 26, 2023 20:57 UTC | Kezar Life Sciences, Inc. KZR · Entity 12111 | Disposition to issuerStock Option (Right to Buy) · Derivative | 8,896 | Not disclosed Strike: $5.60 | Not disclosed |
DisclosureSEC source: 0001209191-23-043425 · doc4.xml · derivative · entry 3 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,896 shares Expires 2030-06-23 F2 · price: On July 24, 2023, the option originally granted to the Reporting Person was amended to reduce the exercise price to $2.28 per share. All of the other terms of the option remain unchanged. F1 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| July 24, 2023 Filed Jul 26, 2023 20:57 UTC | Kezar Life Sciences, Inc. KZR · Entity 12111 | GrantStock Option (Right to Buy) · Derivative | 8,896 | Not disclosed Strike: $2.28 | Not disclosed |
DisclosureSEC source: 0001209191-23-043425 · doc4.xml · derivative · entry 2 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,896 Underlying: Common Stock · 8,896 shares Expires 2029-06-24 F2 · price: On July 24, 2023, the option originally granted to the Reporting Person was amended to reduce the exercise price to $2.28 per share. All of the other terms of the option remain unchanged. F1 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| July 24, 2023 Filed Jul 26, 2023 20:57 UTC | Kezar Life Sciences, Inc. KZR · Entity 12111 | Disposition to issuerStock Option (Right to Buy) · Derivative | 8,896 | Not disclosed Strike: $7.63 | Not disclosed |
DisclosureSEC source: 0001209191-23-043425 · doc4.xml · derivative · entry 1 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,896 shares Expires 2029-06-24 F2 · price: On July 24, 2023, the option originally granted to the Reporting Person was amended to reduce the exercise price to $2.28 per share. All of the other terms of the option remain unchanged. F1 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 20:37 UTC | Kezar Life Sciences, Inc. KZR · Entity 12111 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001209191-23-037930 · doc4.xml · derivative · entry 1 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2033-06-14 F1 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option shall vest on 6/15/2024, subject to Reporting Person continuing to provide service through such date. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 20:56 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 16,532 | $0.00 Strike: $34.33 | $0.00 |
DisclosureSEC source: 0000950170-23-027049 · ownership.xml · derivative · entry 1 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,532 Underlying: Common Stock · 16,532 shares Expires 2033-06-06 F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant and the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date. Read SEC document |
| September 01, 2022 Filed Sep 2, 2022 20:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 10,391 | $0.00 Strike: $55.58 | $0.00 |
DisclosureSEC source: 0000899243-22-030272 · doc4.xml · derivative · entry 1 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,391 Underlying: Common Stock · 10,391 shares Expires 2032-09-01 F1 · derivative.exercise_date: The option vests in full on the first anniversary of the date of grant, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 22:02 UTC | Kezar Life Sciences, Inc. KZR · Entity 12111 | GrantStock Option (right to buy) · Derivative | 26,000 | $0.00 Strike: $4.80 | $0.00 |
DisclosureSEC source: 0001209191-22-038046 · doc4.xml · derivative · entry 1 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2032-06-15 F1 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option shall vest on 6/16/2023, subject to Reporting Person continuing to provide service through such date. Read SEC document |
| May 12, 2022 Filed May 13, 2022 21:04 UTC | Kezar Life Sciences, Inc. KZR · Entity 12111 | GrantStock Option (right to buy) · Derivative | 26,000 | $0.00 Strike: $5.52 | $0.00 |
DisclosureSEC source: 0001209191-22-028906 · doc4.xml · derivative · entry 1 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2032-05-11 F1 · derivative.exercise_date: One thirty-sixth (1/36th) of the shares shall vest on a monthly basis commencing on May 12, 2022, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| January 27, 2022 Filed Jan 31, 2022 17:37 UTC | Applied Molecular Transport Inc. AMTI · Entity 95737 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $8.01 | $0.00 |
DisclosureSEC source: 0001209191-22-005699 · doc4.xml · derivative · entry 1 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2032-01-27 F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest and become exercisable on the Exercisable Date set forth above and 1/48th of the shares subject to the option shall vest monthly thereafter, provided that Reporting Person remains a service provider to the Issuer on each such vest date. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,614 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0000899243-21-027902 · doc4.xml · derivative · entry 14 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,561 Underlying: Common Stock · 2,614 shares Expires 2030-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise reported in this Form 4 was effected pursuant to a 10b5-1 trading plan. F11 · derivative.exercise_date: The option vests as to one third on the first anniversary of the of the vesting commencement date, February 5, 2020, and at a rate of 4.17% each month thereafter until the option is fully vested. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 100 | $129.38 | $12,938.00 |
DisclosureSEC source: 0000899243-21-027902 · doc4.xml · nonDerivative · entry 13 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 100 | $128.67 | $12,867.00 |
DisclosureSEC source: 0000899243-21-027902 · doc4.xml · nonDerivative · entry 12 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 100 | $126.51 | $12,651.00 |
DisclosureSEC source: 0000899243-21-027902 · doc4.xml · nonDerivative · entry 11 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200 Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 300 | $124.31 | $37,293.00 |
DisclosureSEC source: 0000899243-21-027902 · doc4.xml · nonDerivative · entry 10 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.28 to $124.33, inclusive. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 200 | $123.76 | $24,752.00 |
DisclosureSEC source: 0000899243-21-027902 · doc4.xml · nonDerivative · entry 9 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $123.64 to $123.88, inclusive. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 100 | $122.85 | $12,285.00 |
DisclosureSEC source: 0000899243-21-027902 · doc4.xml · nonDerivative · entry 8 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800 Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 400 | $121.59 | $48,636.00 |
DisclosureSEC source: 0000899243-21-027902 · doc4.xml · nonDerivative · entry 7 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.19 to $121.96, inclusive. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 200 | $120.39 | $24,078.00 |
DisclosureSEC source: 0000899243-21-027902 · doc4.xml · nonDerivative · entry 6 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,300 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.37 to $120.40, inclusive. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 100 | $119.68 | $11,968.00 |
DisclosureSEC source: 0000899243-21-027902 · doc4.xml · nonDerivative · entry 5 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.67 to $119.68, inclusive. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 200 | $118.35 | $23,670.00 |
DisclosureSEC source: 0000899243-21-027902 · doc4.xml · nonDerivative · entry 4 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,600 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.00 to $118.71, inclusive. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 200 | $116.41 | $23,282.00 |
DisclosureSEC source: 0000899243-21-027902 · doc4.xml · nonDerivative · entry 3 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,800 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.13 to $116.69, inclusive. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 614 | $115.38 | $70,843.32 |
DisclosureSEC source: 0000899243-21-027902 · doc4.xml · nonDerivative · entry 2 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.04 to $115.88, inclusive. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionCommon Stock | 2,614 | $17.00 | $44,438.00 |
DisclosureSEC source: 0000899243-21-027902 · doc4.xml · nonDerivative · entry 1 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,614 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise reported in this Form 4 was effected pursuant to a 10b5-1 trading plan. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,045 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0000899243-21-026782 · doc4.xml · derivative · entry 7 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,175 Underlying: Common Stock · 12,045 shares Expires 2030-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise reported in this Form 4 was effected pursuant to a 10b5-1 trading plan. F7 · derivative.exercise_date: The option vests as to one third on the first anniversary of the of the vesting commencement date, February 5, 2020, and at a rate of 4.17% each month thereafter until the option is fully vested. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 1,000 | $109.39 | $109,390.00 |
DisclosureSEC source: 0000899243-21-026782 · doc4.xml · nonDerivative · entry 6 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 900 | $108.30 | $97,470.00 |
DisclosureSEC source: 0000899243-21-026782 · doc4.xml · nonDerivative · entry 5 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.12 to $108.60, inclusive. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 1,162 | $107.22 | $124,589.64 |
DisclosureSEC source: 0000899243-21-026782 · doc4.xml · nonDerivative · entry 4 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,900 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.00 to $107.60, inclusive. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 3,196 | $106.28 | $339,670.88 |
DisclosureSEC source: 0000899243-21-026782 · doc4.xml · nonDerivative · entry 3 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,062 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.00 to $106.77, inclusive. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.